Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2022 Apr 29;11(8):915–921. doi: 10.1177/1087057106293295

Discovering Severe Acute Respiratory Syndrome Coronavirus 3CL Protease Inhibitors: Virtual Screening, Surface Plasmon Resonance, and Fluorescence Resonance Energy Transfer Assays

Lili Chen 1, Shuai Chen 1, Chunshan Gui 1, Jianhua Shen 1, Xu Shen 1,2,*, Hualiang Jiang 1,2
PMCID: PMC9050464  PMID: 17092912

Abstract

An integrated system has been developed for discovering potent inhibitors of severe acute respiratory syndrome coronavirus 3C–like protease (SARS-CoV 3CLpro) by virtual screening correlating with surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET) technologies-based assays. The authors screened 81,287 small molecular compounds against SPECS database by virtual screening; 256 compounds were subsequently selected for biological evaluation. Through SPR technology-based assay, 52 from these 256 compounds were discovered to show binding to SARS-CoV 3CLpro. The enzymatic inhibition activities of these 52 SARS-CoV 3CLpro binders were further applied to FRET-based assay, and IC50 values were determined. Based on this integrated assay platform, 8 new SARS-CoV 3CLpro inhibitors were discovered. The fact that the obtained IC50 values for the inhibitors are in good accordance with the discovered dissociation equilibrium constants (KDs) assayed by SPR implied the reliability of this platform. Our current work is hoped to supply a powerful approach in the discovery of potent SARS-CoV 3CLpro inhibitors, and the determined inhibitors could be used as possible lead compounds for further research.

Key words: SARS, SARS-CoV 3CLpro, inhibitor, virtual screening, SPR, FRET

References

  • 1.von Grotthuss M, Wyrwicz LS, Rychlewski L. mRNA cap-1 methyltransferase in the SARS genome. Cell. 2003;113:701–702. doi: 10.1016/S0092-8674(03)00424-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Drosten C, Preiser W, Gunther S, Schmitz H, Doerr HW. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol Med. 2003;9:325–327. doi: 10.1016/S1471-4914(03)00133-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Koch’s postulates fulfilled for SARS virus. Nature. 2003;423:240. doi: 10.1038/423240a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry. 2004;43:4906–4912. doi: 10.1021/bi0361766. [DOI] [PubMed] [Google Scholar]
  • 5.Chen L, Gui C, Luo X, Yang Q, Gunther S, Scandella E, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005;79:7095–7103. doi: 10.1128/JVI.79.11.7095-7103.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Blanchard JE, Elowe NH, Huitema C, Fortin PD, Cechetto JD, Eltis LD, et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol. 2004;11:1445–1453. doi: 10.1016/j.chembiol.2004.08.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Li J, Chen J, Gui C, Zhang L, Qin Y, Xu Q, et al. Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay. Bioorg Med Chem. 2006;14:2209–2224. doi: 10.1016/j.bmc.2005.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cooper MA. Optical biosensors in drug discovery. Nat Rev Drug Discov. 2002;1:515–528. doi: 10.1038/nrd838. [DOI] [PubMed] [Google Scholar]
  • 9.Markgren PO, Hämäläinen M, Danielson UH. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Anal Biochem. 1998;265:340–350. doi: 10.1006/abio.1998.2927. [DOI] [PubMed] [Google Scholar]
  • 10.Du L, Zhang Z, Luo X, Chen K, Shen X, Jiang H. Binding investigation of human 5-lipoxygenase with its inhibitors by SPR technology correlating with molecular docking simulation. J Biochem (Tokyo) 2006;139:715–723. doi: 10.1093/jb/mvj084. [DOI] [PubMed] [Google Scholar]
  • 11.Ye F, Zhang ZS, Luo HB, Shen JH, Chen KX, Shen X, et al. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation. Chembiochem. 2006;7:74–82. doi: 10.1002/cbic.200500186. [DOI] [PubMed] [Google Scholar]
  • 12.Chen S, Chen LL, Luo HB, Sun T, Chen J, Ye F, et al. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. Acta Pharmacol Sin. 2005;26:99–106. doi: 10.1111/j.1745-7254.2005.00010.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chen S, Chen L, Tan J, Chen J, Du L, Sun T, et al. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. J Biol Chem. 2005;280:164–173. doi: 10.1074/jbc.M408211200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sun H, Luo H, Yu C, Sun T, Chen J, Peng S, et al. Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus. Protein Expr Purif. 2003;32:302–308. doi: 10.1016/j.pep.2003.08.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Doman TN, McGovern SL, Witherbee BJ, Kasten TP, Kurumbail R, Stallings WC, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem. 2002;45:2213–2221. doi: 10.1021/jm010548w. [DOI] [PubMed] [Google Scholar]
  • 16.Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001;15:411–428. doi: 10.1023/a:1011115820450. [DOI] [PubMed] [Google Scholar]
  • 17.Cornell WD, Cieplak D, Bayly CI, Gould IR, Merz KM, Ferguson DM, et al. A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem SOC. 1995;117:5179–5197. [Google Scholar]
  • 18.Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-A rapid access to atomic charges. Tetrahedron. 1980;36:3219–3228. [Google Scholar]
  • 19.Purcell WP, Singer JA. Brief review and table of semiempirical parameters used in the Hückel molecular orbital method. J Chem Eng Data. 1967;12:235–246. [Google Scholar]
  • 20.Clark R, Strizhev A, Leonard J, Blake J, Matthew J. Consensus scoring for ligand/protein interactions. J Mol Graph Model. 2002;20:281–295. doi: 10.1016/s1093-3263(01)00125-5. [DOI] [PubMed] [Google Scholar]
  • 21.Zheng S, Luo X, Chen G, Zhu W, Shen J, Chen K, et al. A new rapid and effective chemistry space filter in recognizing a druglike database. J Chem Inf Model. 2005;45:856–862. doi: 10.1021/ci050031j. [DOI] [PubMed] [Google Scholar]
  • 22.Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991;198:268–277. doi: 10.1016/0003-2697(91)90424-r. [DOI] [PubMed] [Google Scholar]
  • 23.Xiong B, Gui CS, Xu XY, Luo C, Chen J, Luo HB, et al. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol Sin. 2003;24:497–504. [PubMed] [Google Scholar]
  • 24.Wang S, Milne GW, Yan X, Posey IJ, Nicklaus MC, Graham L, et al. Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. J Med Chem. 1996;39:2047–2054. doi: 10.1021/jm950874+. [DOI] [PubMed] [Google Scholar]
  • 25.Stahmann MA, Wolff I. Studies on 4-hydroxycoumarins: I. The synthesis of 4-hydroxycoumarins. J Am Chem Soc. 1943;65:2285–2287. [Google Scholar]
  • 26.Sengupta P, Sen M, Karuri P. Structure of gerberinol novel dimethyl-dicoumarol from gerbera lanuginosa benth. J Indian Chem Soc. 1985;62:916–919. [Google Scholar]
  • 27.Luo H, Wu D, Shen C, Chen K, Shen X, Jiang H. Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction. Int J Biochem Cell Biol. 2006;38:589–599. doi: 10.1016/j.biocel.2005.10.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Luo H, Chen Q, Chen J, Chen K, Shen X, Jiang H. The nucleocapsid protein of SARS coronavirus has a high binding affinity to the human cellular heterogeneous nuclear ribonucleoprotein A1. FEBS Lett. 2005;579:2623–2628. doi: 10.1016/j.febslet.2005.03.080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kao RY, To AP, Ng LW, Tsui WH, Lee TS, Tsoi HW, et al. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Lett. 2004;576:325–330. doi: 10.1016/j.febslet.2004.09.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gao Z, Luo H, Chen L, Shen J, Chen K, Jiang H, et al. Determining PPAR-ligand binding affinity using fluorescent assay with cis-parinaric acid as a probe. Science in China Ser B Chemistry. 2005;48:1–10. [Google Scholar]

Articles from Slas Discovery are provided here courtesy of Elsevier

RESOURCES